Hydroxychloroquine is not traditionally classified as a primary immunosuppressant, but it does possess immunomodulatory properties. Originally developed as an antimalarial drug, hydroxychloroquine is widely used to treat autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. In these conditions, the drug helps modulate the immune system by reducing inflammation and the activity of immune cells that attack the body’s own tissues. It does so by interfering with the communication between cells in the immune system, thereby decreasing the production of certain inflammatory cytokines and other mediators that contribute to the autoimmune process.
Unlike stronger immunosuppressants, Hydroxychloroquine 400mg does not completely suppress the immune system, but rather adjusts its activity to reduce pathological immune responses while maintaining overall immune function. This characteristic makes it particularly valuable for long-term management of chronic autoimmune diseases, as it generally has a more favorable safety profile compared to more potent immunosuppressants. Patients on hydroxychloroquine typically experience fewer severe side effects and do not have the same heightened risk of infections that can accompany other immunosuppressive therapies.
In recent years, hydroxychloroquine has gained attention for its potential role in treating and managing other conditions due to its immunomodulatory effects. However, its use outside established indications, such as for COVID-19, remains controversial and is not broadly supported by strong clinical evidence. For autoimmune diseases, hydroxychloroquine continues to be a mainstay of therapy due to its balance of efficacy in reducing disease activity and maintaining an acceptable safety profile.
